Biomarker Inference and the Timing of Next-Generation Sequencing in a Multi-Institutional, Cross-Cancer Clinicogenomic Data Set.
Kenneth L KehlJessica A LaverySamantha BrownHannah E FuchsGregory J RielyDeborah SchragAshley NewcombChelsea NicholsChristine M MicheelPhilippe L BedardShawn M SweeneyMichael FiandaloKatherine S Panageasnull nullPublished in: JCO precision oncology (2024)
To evaluate the appropriateness of a data set for a particular research question, it is crucial to measure associations between dynamic cancer status and the timing of NGS, as well as to evaluate interactions involving biomarkers of interest and NGS timing with respect to survival outcomes.